Angiodysplasia primary prevention: Difference between revisions
Jump to navigation
Jump to search
Nikita Singh (talk | contribs) |
Nikita Singh (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Angiodysplasia}} | {{Angiodysplasia}} | ||
{{CMG}} {{AE}} {{ | {{CMG}}; {{AE}} {{NKT}} | ||
==Primary Prevention== | ==Primary Prevention== | ||
Latest revision as of 10:55, 15 October 2021
|
Angiodysplasia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Angiodysplasia primary prevention On the Web |
|
American Roentgen Ray Society Images of Angiodysplasia primary prevention |
|
Risk calculators and risk factors for Angiodysplasia primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Nikita Singh, M.B.B.S.[2]
Primary Prevention
No method for primary prevention of angiodysplasia has been recognized till date. Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) should be avoided due to its potentially damaging effects on both upper and lower GI.[1]
References
- ↑ Sostres C, Gargallo CJ, Lanas A (2013). "Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage". Arthritis Res Ther. 15 Suppl 3: S3. doi:10.1186/ar4175. PMC 3890944. PMID 24267289.